Recombinant Human Collagen in Clinical Medicine

Abstract

Background

Collagen is the dominant structural protein of vertebrate connective tissues and a central biomaterial in skin, cornea, tendon, cartilage, bone, vessel, oral mucosa, and wound repair. Traditional collagen products have largely been extracted from bovine, porcine, fish, or other animal tissues. Although animal-derived collagens have a long clinical history, they have limitations including batch variability, residual nonhuman epitopes, possible immunogenicity, pathogen-related concerns, ethical constraints, and limited molecular engineering. Recombinant human collagen has emerged as a synthetic-biology alternative designed to reproduce full-length human collagen chains, selected human collagen domains, or engineered humanized collagen-like sequences in controlled expression systems.

Objective

This systematic review and narrative synthesis summarizes the biological basis, production methods, molecular types, benefits, clinical applications, aesthetic uses, safety considerations, and translational limitations of recombinant human collagen, with emphasis on dermatology, wound healing, corneal regeneration, tissue engineering, injectable aesthetics, and dermal rejuvenation.

Methods

A PRISMA-informed systematic search was performed across biomedical databases, publisher platforms, and regulatory sources for literature on recombinant human collagen, recombinant humanized collagen, recombinant type I collagen, recombinant type III collagen, recombinant collagen hydrogels, collagen-based medical devices, dermal fillers, wound healing, corneal substitutes, tissue engineering, photoaging repair, and aesthetic applications. Because the evidence base includes heterogeneous manufacturing papers, in vitro studies, animal experiments, early clinical trials, case series, and regulatory documents, quantitative meta-analysis was not performed.

Results

Recombinant human collagen offers human-sequence design, reduced animal-origin risk, improved batch consistency, scalable manufacturing potential, and engineering flexibility. Type I and type III recombinant collagens are most relevant to dermal, wound, tendon, corneal, and aesthetic applications, whereas type IV, VII, and XVII collagens are increasingly relevant to basement membrane and epidermal adhesion biology. Production remains technically demanding because native collagen requires triple-helix formation and post-translational modifications such as proline hydroxylation. Current strategies include yeast expression with prolyl-4-hydroxylase co-expression, microbial production of collagen-like fragments, mammalian and insect cell systems, transgenic plants, chemical modification, cross-linked microgels, and collagen-based bioinks.

Conclusion

Recombinant human collagen is a platform biomaterial rather than a single product class. Its clinical value depends on matching collagen type, molecular format, formulation, degradation profile, mechanical behavior, and biological indication. In aesthetic medicine, its strongest future role may be regenerative matrix restoration rather than simple volume replacement. Larger randomized trials, long-term safety surveillance, and standardized quality-control methods are required before broad equivalence with established animal collagens, hyaluronic acid fillers, or biostimulatory injectables can be assumed.